Skip to main content

Table 4 Regression models predicting the use of tocilizumab, either combination or monotherapy, using baseline only or baseline and follow-up variables, odds ratios (95% confidence intervals)

From: The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy

  Baseline only Baseline and follow-up
Age, per year 0.99 (0.98, 0.99) 1.05 (1.02, 1.08)
Male vs. female 0.91 (0.75, 1.11) 1.03 (0.48, 2.20)
Disease duration, years 0.99 (0.99, 1.01) 1.06 (1.03, 1.08)
Serologic status*
Negative Reference Reference
Positive 0.66 (0.56–0.78 0.11 (0.04, 0.29)
Missing 0.42 (0.29–0.60) 0.88 (0.38, 2.06)
DMARD use**
csDMARD, baseline 0.71 (0.59–0.86) 0.18 (0.12, 0.27)
TNFi 0.48 (0.26, 0.90)
nonTNFi nonTCZ bDMARD 4.59 (2.91, 7.25)
Only csDMARD 5.83 (3.73, 9.13)
No DMARDs 0.40 (0.18, 0.88)
Glucocorticoid use 0.87 (0.61, 1.23)
CDAI, Severe Reference
Moderate 0.65 (0.46, 0.91)
Low 0.48 (0.33, 0.70)
Remission 0.20 (0.11, 0.37)
Comorbidities, count# 1.16 (1.11, 1.22)
  1. Notes: Odds ratios (95% confidence intervals). Baseline models used logistic regression. Models with follow-up data used mixed generalized linear regression
  2. TCZ tocilizumab; DMARD disease-modifying anti-rheumatic drug; csDMARDs conventional synthetic DMARDs; nonTNFi nonTCZ bDMARD includes all JAK inhibitors, abatacept, and rituximab
  3. ---Not considered at baseline or not significant in univariable screen so not considered in multivariable model or withheld from the model because of problems with convergence
  4. *Serologic status defined as a positive if either rheumatoid factor or anti-CCP antibody were ever positive up to the relevant reference point
  5. **Reference category for DMARD use is the non-use of a give DMARD
  6. #Comorbidities are noted in Table 1. Clinical disease activity index (CDAI) categories defined as remission (CDAI < 2.8), low (CDAI 2.9–10.0), moderate (CDAI 10.1–22.0), and high (CDAI > 22.1)